Regulatory Index News w/c 10 Dec 2018

Here is a selection of this week's latest news from around the world

                                                                                                                                                                                                                                                                                                                         

Launch of largest ever UK lung cancer screening study

The largest ever lung cancer screening project undertaken in the UK has launched in London, aiming to detect lung cancer early among at-risk citizens.

To read more follow this PharmaTimes link

 

Roche wins key cancer drug approval, but taking on Merck remains a challenge

Last week, Tecentriq secured an OK from the Food and Drug Administration for previously untreated patients with metastatic non-squamous non-small cell lung cancer (NSCLC), making it the second checkpoint inhibitor behind Merck's rival Keytruda cleared for use in the first-line lung cancer setting.

To read more follow this BioPharmaDive link

     
 

Axovant drops small molecule development after dementia drug failure

Axovant Sciences will stop developing its small molecule drug portfolio, the company said Monday, following the failure of its experimental drug candidate nelotanserin in a Phase 2 trial of patients with Lewy body dementia who experience REM sleep behavior disorder

To read more follow this BioPharmaDive link

 

Scientists develop revolutionary tech to improve prostate cancer detection

A ‘revolutionary’ new medical software able to pinpoint the area from which surgeons should take a biopsy to detect prostate cancer has been developed by NIHR supported researchers

To read more follow this PharmaTimes link

     
 

CEPI, Imperial College partner for emerging diseases vaccines

The Coalition for Epidemic Preparedness Innovations (CEPI) and Imperial College London have announced a partnership to develop a self-amplifying RNA vaccine platform (saRNA), enabling tailored vaccine production against multiple viral pathogens

To read more follow this PharmaTimes Link

 

Drug Launch of the Year: Amgen and Novartis' Aimovig

Amgen and Novartis, in winning approval for their new migraine drug Aimovig this May, laid first claim to a market Wall Street has pegged as a multi-billion dollar opportunity

To read more follow this BioPharmaDive link

 

L O

Author

Lorna Osborn

Date Published

12th December 2018

Come and join our community!

We are ready and waiting for you

We use cookies. By continuing to browse the site or closing this message you are agreeing to our Terms and Privacy Policy

ACCEPT and Hide This Message